At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Investors
 



Home >> Investor Relations >> Corporate Governance >> Insider Transactions

Insider Transactions

Date Name Title Type Shares Traded Sorted Ascending Price Range
Jul 22, 2008 licholai gregory p Officer Sell 15,000 15.00
Jul 22, 2008 licholai gregory p Officer Option Execute 15,000 0.64
Jun 5, 2007 barris peter j Beneficial Owner (10% or more) Option Execute 15,077 6.38
Jun 5, 2007 kramlich c richard Beneficial Owner (10% or more) Option Execute 15,077 6.38
Jun 5, 2007 new enterprise associates 11 lp Beneficial Owner (10% or more) Option Execute 15,077 6.38
Jun 5, 2007 newhall charles w iii Beneficial Owner (10% or more) Option Execute 15,077 6.38
Jun 5, 2007 perry mark w Beneficial Owner (10% or more) Option Execute 15,077 6.38
Jun 5, 2007 barkas alexander e Director Option Execute 15,119 6.38
Jun 5, 2007 prospect venture partners ii lp Beneficial Owner (10% or more) Option Execute 15,119 6.38
Jul 27, 2007 fhm iv lp Beneficial Owner (10% or more) Buy 17,800 11.26 - 11.50
Jul 27, 2007 topper james n Director Buy 17,800 11.26 - 11.50
Mar 3, 2008 fhm iv lp Beneficial Owner (10% or more) Buy 18,426 9.83 - 10.00
Mar 3, 2008 topper james n Director Buy 18,426 9.83 - 9825.00
Mar 15, 2013 crowley john f Officer Acquisition (Non Open Market) 18,506 3.49
Nov 4, 2009 barer sol j Director Buy 20,000 4.13
Jun 17, 2011 crowley john f Officer Buy 20,000 6.04
Jan 2, 2008 crowley john f Officer Option Execute 20,000 0.64
Apr 24, 2008 palling david Officer Option Execute 20,000 0.64
Dec 2, 2008 patterson matthew r Officer Option Execute 20,098 0.64
Mar 6, 2008 fhm iv lp Beneficial Owner (10% or more) Buy 22,146 9.90 - 10.18
Showing 301-320 of 392 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  See Previous 20 | See Next 20

Stock transaction information provided by EDGAR Online. Amicus Therapeutics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.


Copyright © 2012 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy